Notably, studies have demonstrated that treatment with either anti-PD-1 or anti-type I interferon receptor-1 (IFNAR-1) alone failed to improve the survival rate in a mouse model of HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.